Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pluvicto Dosimetry in Prostate Cancer with Renal or Bone Marrow Impairment
NCT07169825Phase 4Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2026
- Primary completion
- Sep 2026
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 4 trial of lutetium lu 177 vipivotide tetraxetan in prostate cancer (PCa), sponsored by University of Texas MD Anderson Cancer Center. Started Mar 2026; status: recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07169825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07169825.